Plasmacytoid dendritic cells and dermatological disorders: Focus on their role in autoimmunity and cancer

European Journal of Dermatology

Volumn 20, Issue 1, 2010, Pages 16-23

  Charles, Julie ^a,b,c,d   Chaperot, Laurence ^b,c,d   Salameire, Dimitri ^a,b,c,d   Di Domizio, Jérémy ^b,c,d   Aspord, Caroline ^b,c,d   Gressin, Rémy ^a,b,c   Jacob, Marie Christine ^d   Richard, Marie Jeanne ^b,c,d,e   Beani, Jean Claude ^a   Plumas, Joel ^b,c,d   Leccia, Marie Thérèse ^a,b,c,d  

^a HÔPITAL MICHALLON   (France)

^b INSERM   (France)

^c UNIV GRENOBLE ALPES   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Interferon alpha; Lupus; Melanoma; Plasmacytoid dendritic cell; Psoriasis; Toll like receptor ligand

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; BDCA2 MONOCLONAL ANTIBODY; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DEATH RECEPTOR 4; HIGH MOBILITY GROUP B1 PROTEIN; IMIQUIMOD; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ATOPIC DERMATITIS; AUTOIMMUNITY; BASAL CELL CARCINOMA; CLINICAL TRIAL; DENDRITIC CELL; DISCOID LUPUS ERYTHEMATOSUS; GRAFT VERSUS HOST REACTION; HEAD AND NECK CARCINOMA; HUMAN; INTERFERON PRODUCTION; KAPOSI SARCOMA; LEUKEMIA; LICHEN PLANUS; LUPUS VULGARIS; MALIGNANT LENTIGO; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL LEUKEMIA; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 76749103285     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0816     Document Type: Review

References (66)

1. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
2. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol, 2005 [réf à compléter].
3. Ebner S, et al. Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol 2004; 16: 877-87.
4. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-26.
5. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343: 37-49.
6. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008; 26: 293-316.
7. Vermi W, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 2005; 201: 509-15.
8. Kohrgruber N, et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol 2004; 173: 6592-602.
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
10. Bacchetta R, Gregori S, Roncarolo MG. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev 2005; 4: 491-6.
11. Adler HS, Steinbrink K. Tolerogenic dendritic cells in health and disease: friend and foe! Eur J Dermatol 2007; 17: 476-91.
12. Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 2002; 63: 1149-55.
13. Korn T, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
14. Kryczek I, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114: 357-9.
15. Hinrichs CS, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009; 114: 596-9.
16. Eckert F, Schmid U. Identification of plasmacytoid T cells in lymphoid hyperplasia of the skin. Arch Dermatol 1989; 125: 1518-24.
17. Facchetti F, et al. Plasmacytoid T cells in a case of lymphocytic infiltration of skin. A component of the skin-associated lymphoid tissue? J Pathol 1988; 155: 295-300.
18. Toonstra J, van der Putte SC. Plasmacytoid monocytes in Jessner's lymphocytic infiltration of the skin. A valuable clue for the diagnosis. Am J Dermatopathol 1991; 13: 321-8.
19. Jahnsen FL, et al. Involvement of plasmacytoid dendritic cells in human diseases. Hum Immunol 2002; 63: 1201-5.
20. Farkas L, et al. Plasmacytoid dendritic cells (natural interferonalpha/ beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-43.
21. Wenzel J, Tuting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 2007; 16: 454-63.
22. Wenzel J, et al. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. J Am Acad Dermatol 2007; 56: 648-50.
23. Tian J, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-96.
24. Obermoser G, et al. Recruitment of plasmacytoid dendritic cells in ultraviolet irradiation-induced lupus erythematosus tumidus. Br J Dermatol 2009; 160: 197-200.
25. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75.
26. Nestle FO, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43.
27. Lande R, et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol 2004; 173: 2815-24.
28. Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9.
29. Albanesi C, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009; 206: 249-58.
30. Gilliet M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-5.
31. Hashizume H, et al. Compartmental imbalance and aberrant immune function of blood CD123+ (plasmacytoid) and CD11c+ (myeloid) dendritic cells in atopic dermatitis. J Immunol 2005; 174: 2396-403.
32. Wollenberg A, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-102.
33. Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005; 53 (2 Suppl 2): S171-6.
34. De Vries HJ, et al. Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. Br J Dermatol 2006; 154: 361-4.
35. de Vries HJ, et al. Lichen planus remission is associated with a decrease of human herpes virus type 7 protein expression in plasmacytoid dendritic cells. Arch Dermatol Res 2007; 299: 213-9.
36. Gerlini G, et al. Massive recruitment of type I interferon producing plasmacytoid dendritic cells in varicella skin lesions. J Invest Dermatol 2006; 126: 507-9.
37. Donaghy H, et al. Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol 2009; 83: 1952-61.
38. Bontkes HJ, et al. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 2005; 96: 897-901.
39. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008; 15: 39-50.
40. Vermi W, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-68.
41. Salio M, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052-62.
42. Bailly C, V.B. Diagnostic des tumeurs mélaniques cutanées. Enseignement post universitaire.International Academy of pathology French Division. 2005-2006.
43. Wenzel J, et al. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 2005; 124: 37-48.
44. Palamara F, et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173: 3051-61.
45. Steinmann A, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43: 555-6.
46. Wolf IH, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139: 273-6.
47. Zeitouni NC, Dawson K, Cheney RT. Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser. Br J Dermatol 2005; 152: 376-7.
48. Naylor MF, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 (Suppl 66): 66-70.
49. Balch CM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
50. Molenkamp BG, et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007; 13: 2961-9.
51. Molenkamp BG, et al. Local administration of PF-3512676 CpGB instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008; 14: 4532-42.
52. Urosevic M, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.
53. Geisse J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
54. Stary G, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-51.
55. Hartmann E, et al. Identification and functional analysis of tumorinfiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
56. Della Bella S, et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol 2006; 119: 317-29.
57. Arpinati M, et al. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003; 11: 345-56.
58. Fugier-Vivier IJ, et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med 2005; 201: 373-83.
59. Chaperot L, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-7.
60. Jacob MC, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003; 88: 941-55.
61. Penven K, et al. Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol 2003; 13: 161-5.
62. Bendriss-Vermare N, et al. In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia 2004; 18: 1491-8.
63. Chaperot L, et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004; 34: 418-26.
64. Treilleux I, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
65. Zou W, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-46.
66. Speiser DE, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.